Event Banner

Aseptic Technologies for Vaccine Manufacturing (Track 3)

Print this page         

Track 3: Aseptic Technologies for Vaccine Manufacturing

Barrier Isolation Agenda ButtonShare best practices through case studies on how to apply evolving technologies to meet production demands (including those related to biohazard emergencies) and learn tactics to minimize dependence on clean rooms for product integrity and worker safety.

This session will address evolving issues relative to the current state of vaccine manufacturing, how the industry is dealing with these challenges and how technologies are evolving to improve the business. There will also be an emphasis on vaccine manufacturing strategies that might be useful in aseptic production of other pharmaceuticals.

Various approaches and case studies will be presented. One key paradigm addressed will be the trend toward reduction of the physical envelope around the process, and the advantages of “closing” processes. This approach emphasizes the use of appropriate equipment, rather than relying on highly controlled facilities.

At the conclusion of this session, participants will be able to:

  • Understand and address current challenges in vaccine production
  • Apply case study experience to current production processes
  • Utilize new production technologies to improve product integrity and worker safety


Jeff Biskup, CRB Consulting Engineers, Inc.


  • Eric Unrau, CRB Consulting Engineers, Inc.
  • Dicky Abraham, Director Vaccine Manufacturing Sciences & Commercialization, Merck & Co. Inc.
  • Dirk Bohm, Merck-Serono
  • Mark Von Stwolinski, VP Architectural Services, CRB Consulting Engineers, Inc.
  • Mark Pelletier, CRB Consulting Engineers, Inc.
  • Henriette Schubert, NNE Pharmaplan
  • Rob Roy, PE, Senior Consultant, IPS
  • Jason Collins, IPS
  • Emile van Corven, Crucell Holland B.V.
  • Carl Jones, MedImmune
  • Kai Lipinski, Vibalogics GmbH